Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8676534 | 0.81 | GAA (0.31) | — | |
| SCHEMBL475361 | 0.78 | APLNR (0.38) | — | |
| SCHEMBL9754770 | 0.78 | GAA (0.31) | — | |
| SCHEMBL1433982 | 0.77 | ATM (0.33) | — | |
| SCHEMBL10415063 | 0.76 | — | — | |
| SCHEMBL8599635 | 0.76 | CHRNB2 (0.32) | — | |
| SCHEMBL51127 | 0.76 | KMT2A (0.31) | — | |
| SCHEMBL5491826 | 0.74 | APLNR (0.35) | — | |
| SCHEMBL11803872 | 0.74 | FPR3 (0.35) | — | |
| SCHEMBL9439471 | 0.71 | CYP3A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316203-A1 | Compositions and Methods for Inhibition of Cancers | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2451273-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CANCERS | The Ohio State University Research Foundation (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005790-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CANCERS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316203-A1 | Compositions and Methods for Inhibition of Cancers | HCCS, GPX4, HMOX1 | ADAM17 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.